Health and Healthcare
Genzyme, Buy-Out Target, Makes Mass Layoffs: National Employee Morale Day
Published:
Last Updated:
Genzyme (NASDAQ: GENZ), the target of a buyout offer from Sanofi-Aventis, began to lay-off almost 10% of its workforce today. The company would not say exactly what the size of the cuts would be.
Genzyme may have decided on the move to increase margins. Sanofi-Aventis has offered $18.5 billion to buy the smaller company. Genzyme’s board has dismissed the offer as too low.
Sanofi-Aventis recently disclosed that it has lined-up $10 billion in financial backing to close a transaction.
Lay-offs to increase the value of the company? Cruel.
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
